10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2021 | |||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 7, 2022) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Statements of Operations | |||
| Revenues: | |||
| Revenue from contract with customer | $ 16,071,700 | 8,497,100 | 6,557,600 |
| Expenses: | |||
| Research and development | 2,908,100 | 2,735,000 | 2,450,000 |
| Selling, general, and administrative | 1,824,900 | 1,346,000 | 1,341,900 |
| Other operating (income) expense, net | (45,600) | (280,400) | (209,200) |
| Total expenses | 7,124,900 | 4,920,500 | 4,347,800 |
| Income from operations | 8,946,800 | 3,576,600 | 2,209,800 |
| Other income (expense): | |||
| Other income (expense), net | 436,300 | 290,700 | 249,500 |
| Interest expense | (57,300) | (56,900) | (30,200) |
| Total other income (expense) | 379,000 | 233,800 | 219,300 |
| Income before income taxes | 9,325,800 | 3,810,400 | 2,429,100 |
| Income tax expense | 1,250,500 | 297,200 | 313,300 |
| Net income | 8,075,300 | 3,513,200 | 2,115,800 |
| Net income per share - basic (in dollars per share) | 76.40 | 32.65 | 19.38 |
| Net income per share - diluted (in dollars per share) | 71.97 | 30.52 | 18.46 |
| Weighted average shares outstanding - basic (in shares) | 105,700 | 107,600 | 109,200 |
| Weighted average shares outstanding - diluted (in shares) | 112,200 | 115,100 | 114,600 |
| Statements of Comprehensive Income | |||
| Net income | 8,075,300 | 3,513,200 | 2,115,800 |
| Other comprehensive income (loss), net of tax: | |||
| Unrealized (loss) gain on debt securities | (56,400) | 9,100 | 35,900 |
| Unrealized gain (loss) on cash flow hedges | 900 | (900) | (2,500) |
| Comprehensive income | 8,019,800 | 3,521,400 | 2,149,200 |
| Project | |||
| Sanofi | |||
| Product and Service | |||
| Collaboration revenue | |||
| Revenue from contract with customer | 1,902,200 | 1,186,400 | 403,600 |
| Other collaboration | |||
| Revenue from contract with customer | 1,771,100 | 1,186,100 | 1,145,600 |
| Product and Service | |||
| Net product sales | |||
| Revenue from contract with customer | 12,117,200 | 5,567,600 | 4,834,400 |
| Cost of goods sold and of collaboration and contract manufacturing | 1,773,100 | 491,900 | 362,300 |
| Other revenue | |||
| Revenue from contract with customer | 281,200 | 557,000 | 174,000 |
| Cost of collaboration and contract manufacturing | |||
| Cost of goods sold and of collaboration and contract manufacturing | 664,400 | 628,000 | 402,800 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2021 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |